Diminazene aceturate (Berenil), a new use for an old compound?

International Immunopharmacology

Volumn 21, Issue 2, 2014, Pages 342-345

  Kuriakose, Shiby ^a   Uzonna, Jude E ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

Author keywords

African trypanosomiasis; Anti inflammatory agent; Diminazene aceturate (Berenil); Immunomodulation; Management of chronic inflammatory conditions

Indexed keywords

ANTIINFLAMMATORY AGENT; CYTOKINE; DIMINAZENE ACETURATE; MITOGEN ACTIVATED PROTEIN KINASE; STAT PROTEIN; DIMINAZENE; TRANSCRIPTION FACTOR;

AFRICAN TRYPANOSOMIASIS; ANTIINFLAMMATORY ACTIVITY; CYTOKINE PRODUCTION; DRUG MECHANISM; ENZYME INHIBITION; HUMAN; IMMUNOMODULATION; INFLAMMATION; INTRACELLULAR SIGNALING; MACROPHAGE; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PIROPLASMOSIS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REVIEW; ANALOGS AND DERIVATIVES; ANIMAL; DRUG EFFECTS; METABOLISM; SIGNAL TRANSDUCTION;

ANIMALS; CYTOKINES; DIMINAZENE; HUMANS; INFLAMMATION; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS;

EID: 84926368437     PISSN: 15675769     EISSN: 18781705     Source Type: Journal    
DOI: 10.1016/j.intimp.2014.05.027     Document Type: Review

References (38)

1. A.S. Peregrine, and M. Mamman Pharmacology of diminazene: a review Acta Trop 54 3-4 Sep 1993 185 203
2. H. Jensch 4, 4′-Diamidino-diazoaminobenzene, a new agent in the treatment of trypanosomiasis and babesiasis Arzneimittelforschung 5 11 Nov 1955 634 635
3. V.M. Gonzalez, J.M. Perez, and C. Alonso The berenil ligand directs the DNA binding of the cytotoxic drug Pt-berenil J Inorg Biochem 68 4 Dec 1997 283 287
4. G. Riou, and J. Benard Berenil induces the complete loss of kinetoblast DNA sequences in Trypanosoma equiperdum Biochem Biophys Res Commun 96 1 Sep 16, 1980 350 354
5. C. Brack, E. Delain, G. Riou, and B. Festy Molecular organization of the kinetoplast DNA of Trypanosoma cruzi treated with berenil, a DNA interacting drug J Ultrastruct Res 39 5 Jun 1972 568 579
6. T. Haaf, W. Feichtinger, M. Guttenbach, L. Sanchez, C.R. Muller, and M. Schmid Berenil-induced undercondensation in human heterochromatin Cytogenet Cell Genet 50 1 1989 27 33
7. M. Poot, K. Kausch, J. Kohler, T. Haaf, and H. Hoehn The minor-groove binding DNA-ligands netropsin, distamycin A and berenil cause polyploidisation via impairment of the G2 phase of the cell cycle Cell Struct Funct 15 3 Jun 1990 151 157
8. F.R. Rurangirwa, H. Tabel, G.J. Losos, and I.R. Tizard Suppression of antibody response to Leptospira biflexa and Brucella abortus and recovery from immunosuppression after Berenil treatment Infect Immun 26 3 Dec 1979 822 826
9. J.E. Uzonna, R.S. Kaushik, J.R. Gordon, and H. Tabel Cytokines and antibody responses during Trypanosoma congolense infections in two inbred mouse strains that differ in resistance Parasite Immunol 21 2 Feb 1999 57 71
10. E.B. Otesile, and H. Tabel Enhanced resistance of highly susceptible Balb/c mice to infection with Trypanosoma congolense after infection and cure J Parasitol 73 5 Oct 1987 947 953
11. R.O. Arowolo, and F.O. Adepolu The interaction of Berenil with histamine on isolated mammalian tissues Trans R Soc Trop Med Hyg 75 2 1981 302 303
12. H.M. Kellner, H.G. Eckert, and M.H. Volz Studies in cattle on the disposition of the anti-trypanosomal drug diminazene diaceturate (Berenil) Trop Med Parasitol 36 4 Dec 1985 199 204
13. P.A. Onyeyili, and S.M. Anika The influence of Trypanosoma congolense infection on the disposition kinetics of diminazene aceturate in the dog Vet Res Commun 13 3 1989 231 236
14. M. Mamman, Y.O. Aliu, and A.S. Peregrine Comparative pharmacokinetics of diminazene in noninfected Boran (Bos indicus) cattle and Boran cattle infected with Trypanosoma congolense Antimicrob Agents Chemother 37 5 May 1993 1050 1055
15. Y.O. Aliu, M. Mamman, and A.S. Peregrine Pharmacokinetics of diminazene in female Boran (Bos indicus) cattle J Vet Pharmacol Ther 16 3 Sep 1993 291 300
16. M. Mamman, G. Gettinby, N.B. Murphy, S. Kemei, and A.S. Peregrine Frequency of diminazene-resistant trypanosomes in populations of Trypanosoma congolense arising in infected animals following treatment with diminazene aceturate Antimicrob Agents Chemother 39 5 May 1995 1107 1113
17. L.V. Kulemina, and D.A. Ostrov Prediction of off-target effects on angiotensin-converting enzyme 2 J Biomol Screen 16 8 Sep 2011 878 885
18. V. Shenoy, A. Gjymishka, Y.P. Jarajapu, Y. Qi, A. Afzal, K. Rigatto, and et al. Diminazene attenuates pulmonary hypertension and improves angiogenic progenitor cell functions in experimental models Am J Respir Crit Care Med 187 6 Mar 15, 2013 648 657
19. A.P. Mecca, R.W. Regenhardt, T.E. O'Connor, J.P. Joseph, M.K. Raizada, M.J. Katovich, and et al. Cerebroprotection by angiotensin-(1-7) in endothelin-1-induced ischaemic stroke Exp Physiol 96 10 Oct 2011 1084 1096
20. G. Foureaux, J.C. Nogueira, B.S. Nogueira, G.O. Fulgencio, G.B. Menezes, S.O. Fernandes, and et al. Antiglaucomatous effects of the activation of intrinsic Angiotensin-converting enzyme 2 Invest Ophthalmol Vis Sci 54 6 Jun 2013 4296 4306
21. S. Kuriakose, H.M. Muleme, C. Onyilagha, R. Singh, P. Jia, and J.E. Uzonna Diminazene aceturate (Berenil) modulates the host cellular and inflammatory responses to Trypanosoma congolense infection PLoS One 7 11 2012 e48696
22. H. Tabel, G. Wei, and M. Shi T cells and immunopathogenesis of experimental African trypanosomiasis Immunol Rev 225 Oct 2008 128 139
23. S. Kuriakose Diminazene aceturate (Berenil) modulates LPS induced proinflammatory cytokine production by inhibiting phosphorylation of MAPKs and STAT proteins Innate Immun 2013 Oct 31 [Epub ahead of print] PMID: 24179040
24. S.Y. Park, Y.H. Baik, J.H. Cho, S. Kim, K.S. Lee, and J.S. Han Inhibition of lipopolysaccharide-induced nitric oxide synthesis by nicotine through S6K1-p42/44 MAPK pathway and STAT3 (Ser 727) phosphorylation in Raw 264.7 cells Cytokine 44 1 Oct 2008 126 134
25. J.X. Wang, L.F. Hou, Y. Yang, W. Tang, Y. Li, and J.P. Zuo SM905, an artemisinin derivative, inhibited NO and pro-inflammatory cytokine production by suppressing MAPK and NF-kappaB pathways in RAW 264.7 macrophages Acta Pharmacol Sin 30 10 Oct 2009 1428 1435
26. S. Wormald, and D.J. Hilton Inhibitors of cytokine signal transduction J Biol Chem 279 2 Jan 9, 2004 821 824
27. A. Gil Polyunsaturated fatty acids and inflammatory diseases Biomed Pharmacother 56 8 Oct 2002 388 396
28. N. Fujiwara, and K. Kobayashi Macrophages in inflammation Curr Drug Targets Inflamm Allergy 4 3 Jun 2005 281 286
29. A.M. Badger, J.N. Bradbeer, B. Votta, J.C. Lee, J.L. Adams, and D.E. Griswold Pharmacological profile of SB 203580, a selective inhibitor of cytokine suppressive binding protein/p38 kinase, in animal models of arthritis, bone resorption, endotoxin shock and immune function J Pharmacol Exp Ther 279 3 Dec 1996 1453 1461
30. A.M. Badger, D.E. Griswold, R. Kapadia, S. Blake, B.A. Swift, S.J. Hoffman, and et al. Disease-modifying activity of SB 242235, a selective inhibitor of p38 mitogen-activated protein kinase, in rat adjuvant-induced arthritis Arthritis Rheum 43 1 Jan 2000 175 183
31. E. Hollenbach, M. Neumann, M. Vieth, A. Roessner, P. Malfertheiner, and M. Naumann Inhibition of p38 MAP kinase- and RICK/NF-kappaB-signaling suppresses inflammatory bowel disease FASEB J 18 13 Oct 2004 1550 1552
32. C.S. Piao, J.B. Kim, P.L. Han, and J.K. Lee Administration of the p38 MAPK inhibitor SB203580 affords brain protection with a wide therapeutic window against focal ischemic insult J Neurosci Res 73 4 Aug 15, 2003 537 544
33. M. Bianchi, P. Ulrich, O. Bloom, M. Meistrell III, G.A. Zimmerman, H. Schmidtmayerova, and et al. An inhibitor of macrophage arginine transport and nitric oxide production (CNI-1493) prevents acute inflammation and endotoxin lethality Mol Med 1 3 Mar 1995 254 266
34. K. Kerlund, H. Erlandsson Harris, K.J. Tracey, H. Wang, T. Fehniger, L. Klareskog, and et al. Anti-inflammatory effects of a new tumour necrosis factor-alpha (TNF-alpha) inhibitor (CNI-1493) in collagen-induced arthritis (CIA) in rats Clin Exp Immunol 115 1 Jan 1999 32 41
35. J.C. Lee, S. Kumar, D.E. Griswold, D.C. Underwood, B.J. Votta, and J.L. Adams Inhibition of p38 MAP kinase as a therapeutic strategy Immunopharmacology 47 2-3 May 2000 185 201
36. M. Kohno, and J. Pouyssegur Targeting the ERK signaling pathway in cancer therapy Ann Med 38 3 2006 200 211
37. F. Hayakawa, K. Sugimoto, Y. Harada, N. Hashimoto, N. Ohi, S. Kurahashi, and et al. A novel STAT inhibitor, OPB-31121, has a significant antitumor effect on leukemia with STAT-addictive oncokinases Blood Cancer J 3 2013 e166
38. Y. Qiu, P.K. Shil, P. Zhu, H. Yang, A. Verma, B. Lei, and Q. Li Angiotensin-converting enzyme 2 (ACE2) activator DIZE ameliorates endotoxin-induced uveitis in mice IOVS 2014 May 22 PMID: 24854854